Kim et al. discovered that p16, RASSF1A, H-cadherin, and RAR beta gene methylation in tumors may be valuable biomarkers for the early diagnosis of NSCLC in BALF [20]. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.